Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Intervalo de ano de publicação
5.
Graefes Arch Clin Exp Ophthalmol ; 237(10): 840-7, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10502059

RESUMO

BACKGROUND: The purpose of this study was to evaluate microspheres of PLGA containing cyclosporin (CsA) as a subconjunctival drug delivery system and to test their efficacy in the prevention of corneal allograft rejection in the rabbit. METHODS: Rabbits were injected subconjunctivally with a solution of CsA (CsA-AR) (20 animals) or a microsphere suspension of CsA (CsA-MP) (20 animals), with equivalent drug concentrations (15 mg/ml). The concentration of CsA in the aqueous, cornea and blood was measured by radioimmunoassay at different times thereafter. In other rabbits, 40 allogeneic grafts were performed. Animals were divided into four groups that received the following subconjunctival treatments: group 1: AR solution (solvents of CsA-AR solution); group 2: CsA-AR solution; group 3: MP suspension (empty microspheres); group 4: CsA-MP suspension. RESULTS: Mean corneal levels of CsA were 1174+/-830, 918+/-179, 972+/-580, 268+/-182 and 243+/-162 ng/ml at 12, 24 and 48 h and 7 and 14 days after the injection of CsA-AR. For the CsA-MP suspension, corneal concentrations were 1195+/-321, 234+/-147 and 88+/-77 ng/ml at 12, 24 and 48 h but subsequently dropped to undetectable levels. Blood and aqueous levels were undetectable. Treatment with CsA significantly improved the survival time and survival rate of grafts in the CsA-treated groups (2, 4) over grafts in non-CsA-treated groups (1, 3). There was no significant difference in the graft survival curve between groups 2 and 4. CONCLUSION: CsA-containing microspheres might be a promising formulation in the prevention of corneal graft rejection. Since the levels of CsA in blood were undetectable, this treatment might avoid the problems associated with systemic side effects.


Assuntos
Materiais Biocompatíveis , Transplante de Córnea , Ciclosporina/administração & dosagem , Sistemas de Liberação de Medicamentos , Rejeição de Enxerto/prevenção & controle , Imunossupressores/administração & dosagem , Ácido Láctico , Ácido Poliglicólico , Polímeros , Animais , Humor Aquoso/metabolismo , Túnica Conjuntiva , Córnea/metabolismo , Córnea/patologia , Transplante de Córnea/patologia , Ciclosporina/farmacocinética , Modelos Animais de Doenças , Rejeição de Enxerto/metabolismo , Rejeição de Enxerto/patologia , Sobrevivência de Enxerto , Imunossupressores/farmacocinética , Injeções , Microesferas , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Coelhos , Radioimunoensaio , Resultado do Tratamento
7.
J Fr Ophtalmol ; 6(1): 43-9, 1983.
Artigo em Francês | MEDLINE | ID: mdl-6601673

RESUMO

Ultrasonographic examination of leukokoria has proved useful to demonstrate the presence of an intraocular mass and to confirm a suspected retinoblastoma. However, some retinoblastomas present atypical clinical and ultrasonic appearances leading to errors in diagnosis. The ultrasonic characteristics of the two classic types, are presented, together with a third type in which the appearance is diffuse or pseudoinflammatory, one case having been previously misdiagnosed as sub-clinical endophthalmitis. The different characteristics of the three types and their relationship with histologic forms are discussed.


Assuntos
Neoplasias Oculares/diagnóstico , Retinoblastoma/diagnóstico , Ultrassonografia , Pré-Escolar , Diagnóstico Diferencial , Endoftalmite/diagnóstico , Neoplasias Oculares/patologia , Neoplasias Oculares/cirurgia , Humanos , Lactente , Retinoblastoma/patologia , Retinoblastoma/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...